A long-term survival case of small cell lung cancer in an HIV-infected patient

Japanese Journal of Clinical Oncology

Volumn 35, Issue 6, 2005, Pages 349-352

  Kato, Tetsuro ^a   Ieki, Ryuji ^a   Saito, Erika ^a   Ota, Tomohiro ^a   Yuasa, Kazumi ^a   Iguchi, Mari ^a   Okamura, Tatsuru ^a   Shibuya, Masahiko ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Highly active antiretroviral therapy (HAART); Human immunodeficiency virus (HIV); Small cell lung cancer

Indexed keywords

ABACAVIR; AMPRENAVIR; AMRUBICIN; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DIDANOSINE; EFAVIRENZ; IRINOTECAN; NEURON SPECIFIC ENOLASE; PROGASTRIN RELEASING PEPTIDE; RITONAVIR; TUMOR MARKER; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CAMPTOTHECIN; CARBAMIC ACID DERIVATIVE; DRUG DERIVATIVE; OXAZINE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; CASE REPORT; COMORBIDITY; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; LUNG SMALL CELL CANCER; MALE; PROGNOSIS; SURVIVAL TIME; THORAX RADIOGRAPHY; TREATMENT OUTCOME; COMPUTER ASSISTED TOMOGRAPHY; DRUG ADMINISTRATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LUNG TUMOR; MIDDLE AGED; RADIOGRAPHY; SMALL CELL CARCINOMA;

ANTI-HIV AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAMPTOTHECIN; CARBAMATES; CARBOPLATIN; CARCINOMA, SMALL CELL; CISPLATIN; DIDANOSINE; DIDEOXYNUCLEOSIDES; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OXAZINES; RITONAVIR; SULFONAMIDES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 23844541427     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi093     Document Type: Article

References (12)

1. Bower M, Powles T, Nelson M, Shah P, Cox S, Mandelia S, et al. HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003;17:371-5.
2. Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer 2004;101:317-24.
3. Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003;21:3447-53.
4. Parker MS, Leveno DM, Campbell TJ, Worrell JA, Carozza SE. AIDS-related bronchogenic carcinoma: Fact or fiction? Chest 1998;113:154-61.
5. Rankin JA, Collman R, Daniele RP. Acquired immune deficiency syndrome and the lung. Chest 1988;94:155-64.
6. Tirelli U, Spina M, Sandri S, Serraino D, Gobitti C, Fasan M, et al. Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors. Cancer 2000;88:563-9.
7. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Impact of comorbidity on lung cancer survival. Int J Cancer 2003;103:792-802.
8. Vyzula R, Remick SC. Lung cancer in patients with HIV-infection. Lung Cancer 1996;15:325-39.
9. Moses AV, Williams S, Heneveld ML, Strussenberg J, Rarick M, Loveless M, et al. Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood 1996;87:919-25.
10. Sparano JA, Lee S, Henry DF, Ambinder RF, Von Roenn J, Tirelli U, et al. Infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin's lymphoma: A review of the Einstein, Aviano, and ECOG experience in 182 patients. J Acquir Immune Defic Syndr 2000;23:A11, abstract S15.
11. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, et al. Protease inhibitors as inhibitors of human cytochrome P450: high risk associated with ritonavir. J Clin Pharmacol 1998;38:106-11.
12. Yana T, Negoro S, Takada Y, Yokota S, Fukuoka M and West Japan Lung Cancer Group. Phase I study of amrubicin (SM-5887), a 9-amino-anthracycline, in previously untreated patients with extensive stage small-cell lung cancer (ES-SCLC). Proc Am Soc Clin Oncol 1998;17:450a.